The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
The cost-effectiveness of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) and entecavir (ETV) was assessed in patients with chronic hepatitis B in Taiwan.TAF was associated with fewer liver disease events, fewer cases of bone and renal complications, and higher eAG and sAG seroconversion compared with TDF and ETV; TAF was found to be cost-effective compared with both treatments.
Authors
- Nandita Kachru (ORCID: https://orcid.org/0000-0002-2754-0723)
- Pongo Peng
- Elise Chia‐Hui Tan (ORCID: https://orcid.org/0000-0002-8115-3011)
- Sushanth Jeyakumar
- Alon Yehoshua (ORCID: https://orcid.org/0009-0009-2920-916X)
- Nathaniel Smith (ORCID: https://orcid.org/0000-0002-9215-8109)
- Amy Lin
Institutions
- China Medical University (TW)
- Ministry of Health and Welfare (TW)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- MDM Policy & Practice
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/23814683251328659
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences